Forskning ved Københavns Universitet - Københavns Universitet

Forside

Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). / Boisen, Ida Marie; Mos, Iris; Lerche-Black, Eva Merete; Juul, Anders; Bräuner-Osborne, Hans; Blomberg Jensen, Martin.

I: The Journal of clinical endocrinology and metabolism, Bind 105, Nr. 4, 01.04.2020, s. e1322-e1330.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Boisen, IM, Mos, I, Lerche-Black, EM, Juul, A, Bräuner-Osborne, H & Blomberg Jensen, M 2020, 'Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)', The Journal of clinical endocrinology and metabolism, bind 105, nr. 4, s. e1322-e1330. https://doi.org/10.1210/clinem/dgz205

APA

Boisen, I. M., Mos, I., Lerche-Black, E. M., Juul, A., Bräuner-Osborne, H., & Blomberg Jensen, M. (2020). Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). The Journal of clinical endocrinology and metabolism, 105(4), e1322-e1330. https://doi.org/10.1210/clinem/dgz205

Vancouver

Boisen IM, Mos I, Lerche-Black EM, Juul A, Bräuner-Osborne H, Blomberg Jensen M. Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). The Journal of clinical endocrinology and metabolism. 2020 apr 1;105(4):e1322-e1330. https://doi.org/10.1210/clinem/dgz205

Author

Boisen, Ida Marie ; Mos, Iris ; Lerche-Black, Eva Merete ; Juul, Anders ; Bräuner-Osborne, Hans ; Blomberg Jensen, Martin. / Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). I: The Journal of clinical endocrinology and metabolism. 2020 ; Bind 105, Nr. 4. s. e1322-e1330.

Bibtex

@article{b1c477384e23452ba035127b1adf1952,
title = "Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)",
abstract = "CONTEXT: Several heterozygous loss-of-function mutations in the calcium-sensing receptor gene (CASR) leading to elevated ionized serum calcium and familial hypocalciuric hypercalcemia 1 (FHH1) have been characterized. Few mutations are not pathogenic, and previous studies suggested that the Q459R mutation does not result in an FHH1 phenotype.OBJECTIVE: We identified a family with a heterozygous CASR Q459R mutation and characterized their calcium homeostasis and the pathophysiological mechanisms of a homozygous and heterozygous Q459R mutation in vitro.DESIGN: The index patient and her family had clinical, biochemical, and genetic analyses performed. In vitro functional characterization of homozygous and heterozygous (Q459R) mutations was conducted by determining CaSR cell-surface expression and inositol monophosphate (IP1) signaling in transiently transfected human embryonic kidney 293A (HEK293A) cells.RESULTS: All 3 heterozygous carriers had mild asymptomatic hypercalcemia, hypocalciuria, and 2 had elevated serum parathyroid hormone (PTH). In vitro characterization in HEK293A cells revealed that CASR Q459R is a loss-of-function mutation with no impact on cell-surface expression. Cells with the homozygous Q459R genotype had significantly reduced calcium potency of IP1 signaling compared to wild type, whereas the heterozygous Q459R also had lower calcium potency albeit not significantly different from wild type.CONCLUSION: A loss-of-function Q459R mutation in CASR in a family caused FHH1 characterized by elevated ionized calcium and PTH and low calcium excretion. The marked presence of CaSR at the membrane and inhibition of IP1 signaling in vitro suggest that calcimimetics may be functional in patients with this mutation, which seems to be a mild loss-of-function mutation associated with autosomal dominant transmission of FHH1.",
author = "Boisen, {Ida Marie} and Iris Mos and Lerche-Black, {Eva Merete} and Anders Juul and Hans Br{\"a}uner-Osborne and {Blomberg Jensen}, Martin",
note = "{\circledC} Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2020",
month = "4",
day = "1",
doi = "10.1210/clinem/dgz205",
language = "English",
volume = "105",
pages = "e1322--e1330",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1)

AU - Boisen, Ida Marie

AU - Mos, Iris

AU - Lerche-Black, Eva Merete

AU - Juul, Anders

AU - Bräuner-Osborne, Hans

AU - Blomberg Jensen, Martin

N1 - © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - CONTEXT: Several heterozygous loss-of-function mutations in the calcium-sensing receptor gene (CASR) leading to elevated ionized serum calcium and familial hypocalciuric hypercalcemia 1 (FHH1) have been characterized. Few mutations are not pathogenic, and previous studies suggested that the Q459R mutation does not result in an FHH1 phenotype.OBJECTIVE: We identified a family with a heterozygous CASR Q459R mutation and characterized their calcium homeostasis and the pathophysiological mechanisms of a homozygous and heterozygous Q459R mutation in vitro.DESIGN: The index patient and her family had clinical, biochemical, and genetic analyses performed. In vitro functional characterization of homozygous and heterozygous (Q459R) mutations was conducted by determining CaSR cell-surface expression and inositol monophosphate (IP1) signaling in transiently transfected human embryonic kidney 293A (HEK293A) cells.RESULTS: All 3 heterozygous carriers had mild asymptomatic hypercalcemia, hypocalciuria, and 2 had elevated serum parathyroid hormone (PTH). In vitro characterization in HEK293A cells revealed that CASR Q459R is a loss-of-function mutation with no impact on cell-surface expression. Cells with the homozygous Q459R genotype had significantly reduced calcium potency of IP1 signaling compared to wild type, whereas the heterozygous Q459R also had lower calcium potency albeit not significantly different from wild type.CONCLUSION: A loss-of-function Q459R mutation in CASR in a family caused FHH1 characterized by elevated ionized calcium and PTH and low calcium excretion. The marked presence of CaSR at the membrane and inhibition of IP1 signaling in vitro suggest that calcimimetics may be functional in patients with this mutation, which seems to be a mild loss-of-function mutation associated with autosomal dominant transmission of FHH1.

AB - CONTEXT: Several heterozygous loss-of-function mutations in the calcium-sensing receptor gene (CASR) leading to elevated ionized serum calcium and familial hypocalciuric hypercalcemia 1 (FHH1) have been characterized. Few mutations are not pathogenic, and previous studies suggested that the Q459R mutation does not result in an FHH1 phenotype.OBJECTIVE: We identified a family with a heterozygous CASR Q459R mutation and characterized their calcium homeostasis and the pathophysiological mechanisms of a homozygous and heterozygous Q459R mutation in vitro.DESIGN: The index patient and her family had clinical, biochemical, and genetic analyses performed. In vitro functional characterization of homozygous and heterozygous (Q459R) mutations was conducted by determining CaSR cell-surface expression and inositol monophosphate (IP1) signaling in transiently transfected human embryonic kidney 293A (HEK293A) cells.RESULTS: All 3 heterozygous carriers had mild asymptomatic hypercalcemia, hypocalciuria, and 2 had elevated serum parathyroid hormone (PTH). In vitro characterization in HEK293A cells revealed that CASR Q459R is a loss-of-function mutation with no impact on cell-surface expression. Cells with the homozygous Q459R genotype had significantly reduced calcium potency of IP1 signaling compared to wild type, whereas the heterozygous Q459R also had lower calcium potency albeit not significantly different from wild type.CONCLUSION: A loss-of-function Q459R mutation in CASR in a family caused FHH1 characterized by elevated ionized calcium and PTH and low calcium excretion. The marked presence of CaSR at the membrane and inhibition of IP1 signaling in vitro suggest that calcimimetics may be functional in patients with this mutation, which seems to be a mild loss-of-function mutation associated with autosomal dominant transmission of FHH1.

U2 - 10.1210/clinem/dgz205

DO - 10.1210/clinem/dgz205

M3 - Journal article

C2 - 32160303

VL - 105

SP - e1322-e1330

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 242357179